Blinatumomab Consolidation in High-Risk Ph-Negative B-Cell Acute Lymphoblastic Leukemia: Insights from the GRAALL-2014/B-QUEST Study

Highlight

• Blinatumomab consolidation markedly improves minimal residual disease (MRD) clearance in high-risk Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL).
• Integration of blinatumomab reduces relapse rates and significantly prolongs 5-year disease-free and overall survival.
• Patients eligible for allogeneic hematopoietic stem cell transplantation (alloHSCT) benefit overall, though blinatumomab’s additive benefit post-transplant remains unclear.
• Findings support frontline inclusion of blinatumomab and suggest need for prospective evaluation of transplantation strategies in this setting.

Study Background